📢 #NewPaper: New mechanism identified that shields persister tumour cells from the immune system.

✍️ @valeramponi.bsky.social #ManuelSerrano et al.

📰 #CancerResearch @theaacr.bsky.social

➡️ bit.ly/40x4nrI

📌 DOI: 10.1158/0008-5472.CAN-24-0529

#Oncosky #PersisterCells #Senescence 🧪

🗣️“The goal is to be able to develop drugs that selectively target #PersisterCells and strengthen the effect of conventional treatments,” says Dr. @valeramponi.bsky.social.

💕Mil gracias La Voz de la Salud
por este artículo sobre #TesisInternacionales de nuestro grupo #MicroTM #Inibic Que orgullo!!! #SomosChuac #MePRAM #Phagetherapy #BacterialTolerance #PersisterCells #CRISPR 🧬 @phagesantipers.bsky.social

www.lavozdegalicia.es/noticia/coru...

🥳 Our 7th most downloaded article in 2024:

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities by Bardelli, Russo et. al
https://bit.ly/3CkSE...

#persistercells #DTPs #cancerresistance

@natureportfolio.bsky.social #NRCtop10of2024

A team led by Dr. Manuel Serrano at @irbbarcelona.org has discovered a key strategy through which these #PersisterCells evade the immune response and resist #CancerTreatments.

Specifically, the study reveals that #PersisterCells block the genes responsible for #inflammation through an epigenetic mechanism that acts as a 'molecular lock,' preventing these genes from becoming activated and alerting the immune system.

This discovery marks a step forward in the fight against resistance to cancer treatment. By targeting #PersisterCells, the likelihood of relapse could be reduced, thus improving patient prognosis.

➡️ bit.ly/40xlXfl

📌DOI: 10.1158/0008-5472.CAN-24-0529

#IRBScience

#Osimertinib was originally developed to overcome resistance to earlier treatment versions, when resistance to it often begins with a small population of #PersisterCells. The study aimed to uncover signaling changes underlying how these cells survive, and to identify new therapeutic targets.